Search Result
Results for "
hepatic disease
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0247
-
Torasemide
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .
|
-
-
- HY-D1168
-
|
Fluorescent Dye
|
Metabolic Disease
|
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
|
-
-
- HY-12756
-
E6446
1 Publications Verification
|
Toll-like Receptor (TLR)
Stearoyl-CoA Desaturase (SCD)
|
Metabolic Disease
Inflammation/Immunology
|
E6446 is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-111534
-
-
-
- HY-151959
-
|
FXR
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
FXR agonist 4 (compound 10a) is an agonist of farnesoid X receptor (FXR) with an EC50 value of 1.05 μM. FXR agonist 4 effectively improves hyperlipidemia, hepatic steatosis, insulin resistance and hepatic inflammation in DIO mice. FXR agonist 4 can be used for the research of non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-111179
-
|
Others
|
Inflammation/Immunology
|
ML261 is a hepatic lipid droplets formation inhibitor with an IC50 value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation .
|
-
-
- HY-N2831
-
|
Others
|
Others
|
Agrimonolide 6-O-β-D-glucoside is a isocoumarin that can be isolated from Agrimonia pilosa. Agrimonolide 6-O-β-D-glucoside is used in hepatic disease research .
|
-
-
- HY-153491
-
ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx
|
Others
|
Cardiovascular Disease
|
Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
|
-
-
- HY-153491A
-
ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium
|
Others
|
Cardiovascular Disease
|
Olezarsen sodium is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
|
-
-
- HY-47888
-
|
Integrin
|
Inflammation/Immunology
|
PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.
|
-
-
- HY-W127408
-
|
Biochemical Assay Reagents
|
Others
|
1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.
|
-
-
- HY-33298
-
|
|
|
LM10 is a potent inhibitor of tryptophan 2,3-dioxygenase (TDO). Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. LM10 has the potential for the research of cancer diseases .
|
-
-
- HY-B0247S
-
Torasemide-d7
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
Metabolic Disease
|
Torsemide-d7 is the deuterium labeled Torsemide. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis[1][1][3].
|
-
-
- HY-105168
-
|
Endothelin Receptor
|
Cardiovascular Disease
|
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
|
-
-
- HY-B0247R
-
Torasemide (Standard)
|
Others
|
Cardiovascular Disease
Metabolic Disease
|
Torsemide (Standard) is the analytical standard of Torsemide. This product is intended for research and analytical applications. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis .
|
-
-
- HY-B1334A
-
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina .
|
-
-
- HY-B1334
-
|
Mitochondrial Metabolism
Apoptosis
|
Cardiovascular Disease
Cancer
|
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina .
|
-
-
- HY-161139
-
|
JAK
|
Inflammation/Immunology
|
JAK1-IN-14 (Compound 12a) is a potent and selective JAK1 inhibitor. JAK1-IN-14 inhibits JAK1 and JAK2 with an IC50 value of 12.6 nM and 135 nM. JAK1-IN-14 suppresses hepatic fibrosis levels and can be used for the research of liver fibrosis and inflammatory diseases .
|
-
-
- HY-139230
-
|
Cannabinoid Receptor
PPAR
|
Metabolic Disease
|
OLHHA is a dual CB1 receptor antagonist and PPARα agonist. OLHHA also is a alcohol intake inhibitor with an EC50 value of 0.2 mg/kg. OLHHA reduces both hepatic lipid accumulation and circulating triglyceride levels. OLHHA shows anti-steatotic activity and has the potential for the research of non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-12756A
-
|
|
|
E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-141645
-
WS070117
|
AMPK
TGF-β Receptor
NF-κB
JNK
AP-1
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis .
|
-
-
- HY-N0946
-
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Glucosidase
|
Metabolic Disease
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
-
- HY-122591
-
|
COX
|
Metabolic Disease
Cancer
|
PTUPB is a potent and dual sEH and COX-2 enzymes inhibitor with IC50 of 0.9 nM and 1.26 μM, respectively .
|
-
-
- HY-133019
-
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor, with an IC50 of 15.3 nM. ATX inhibitor 5 shows anti-hepatofibrosis effects and reduces CCl4-induced hepatic fibrosis level prominently .
|
-
-
- HY-113478S
-
|
Isotope-Labeled Compounds
|
Infection
Metabolic Disease
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].
|
-
-
- HY-N7864
-
all-cis-4,7,10,13,16-Docosapentaenoic acid; Osbond acid
|
Biochemical Assay Reagents
|
Others
|
Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.
|
-
-
- HY-B0378A
-
RS-10085
|
Angiotensin-converting Enzyme (ACE)
Apoptosis
|
Cardiovascular Disease
|
Moexipril hydrochloride (RS-10085) is an orally active inhibitor of angiotensin-converting enzyme (ACE), and becomes effective by being hydrolyzed to moexiprila (hydrochloride). Moexipril hydrochloride exhibits antihypertensive and neuroprotective effects - .
|
-
-
- HY-117281
-
-
-
- HY-N0110
-
-
-
- HY-N0110B
-
-
-
- HY-N0110R
-
|
Apoptosis
Virus Protease
Indoleamine 2,3-Dioxygenase (IDO)
Parasite
Bacterial
Aurora Kinase
|
Cancer
|
Palmatine (chloride) (Standard) is the analytical standard of Palmatine (chloride). This product is intended for research and analytical applications. Palmatine chloride is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC50s of 3 μM and 157μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine chloride can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC50 of 96 μM. Palmatine chloride shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities .
|
-
Cat. No. |
Product Name |
Type |
-
- HY-D1168
-
|
Fluorescent Dyes/Probes
|
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses .
|
Cat. No. |
Product Name |
Type |
-
- HY-N7864
-
all-cis-4,7,10,13,16-Docosapentaenoic acid; Osbond acid
|
Biochemical Assay Reagents
|
Docosapentaenoic acid (DPA) is a 22-carbon fatty acid found in fish oil. It is a minor component of total serum unsaturated fatty acids in humans, ranging from 0.1% to 1%, and increasing with dietary supplementation. all-cis-4,7,10,13,16-DPA, also known as Austrian acid, is an isomer of DPA. It is an omega-6 fatty acid formed by the extension and desaturation of arachidonic acid. During fatty acid desaturase syndrome, levels of this fatty acid may be reduced, which may affect development. Upregulated hepatic elongate expression of very long fatty acid protein 6 and elevated levels of very long chain fatty acids, including all-cis 4,7,10,13,16-DPA, are characteristic of nonalcoholic steatohepatitis, a precancerous disease of hepatocellular carcinoma.
|
-
- HY-W127408
-
|
Biochemical Assay Reagents
|
1,2,3-Tripalmitoleoyl-rac-glycerol is a triacylglycerol containing palmitoleic acid at the sn-1, sn-2 and sn-3 positions. It reduces erythrocyte deformability in a concentration-dependent manner in the Reid filtration assay. Hepatic levels of 1,2,3-tripalmitoleoyl-rac-glycerol are increased in a JAK2L mouse model of hepatic steatosis. 1,2,3-Tripalmitoleoyl-rac-glycerol plasma levels are reduced in patients with predialysis renal disease.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-105168
-
|
Endothelin Receptor
|
Cardiovascular Disease
|
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0247S
-
|
Torsemide-d7 is the deuterium labeled Torsemide. Torsemide (Torasemide) is an orally active loop diuretic. Torsemide has anti-aldosterone and vasodilatory effects. Torsemide also can be used for the research of heart failure, renal disease and hepatic cirrhosis[1][1][3].
|
-
-
- HY-113478S
-
|
Ursodeoxycholic acid-2,2,4,4-d4 is the deuterium labeled Ursodeoxycholic acid (HY-13771). Ursodeoxycholic acid is a secondary bile acid issued from the transformation of (cheno)deoxycholic acid by intestinal bacteria, acting as a key regulator of the intestinal barrier integrity and essential for lipid metabolism. Ursodeoxycholic acid acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, including G-protein coupled bile acid receptor 5 (TGR5, GPCR19) and the farnesoid X receptor (FXR). Ursodeoxycholic acid can be used for the research of a variety of hepatic and gastrointestinal diseases. Ursodeoxycholic acid also reduces ACE2 expression and is beneficial for reducing SARS-CoV-2 infection[1][2][3][4][5].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: